IBI363

IBI363 is a fusion protein developed by Innovent Biologics (Suzhou). Its target is PD-1 (the sponsor names IL-2 pathway x PD-1). The sponsor states: A mutated IL-2 cytokine fused to an anti-PD-1 antibody, combining IL-2 pathway stimulation with PD-1 checkpoint blockade in a single molecule. ClinicalTrials.gov describes the intervention as: a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in melanoma, non-small-cell lung cancer, colorectal cancer and renal cell carcinoma. The largest, NCT06797297, plans to enrol 180 participants with primary completion expected 2026-03-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.